VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of$ 0.41. This compares to loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 14.63%. A quarter ago, it was expected that this company would post a loss of$ 0.34 per share when it actually produced a loss of $0.25, delivering a surprise of 26.47%. Over the last four quarters, the compan ...